Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular disease

Objective

Every year chronic cardiac disease causes 3.9 million deaths in Europe, that’s a death every 8 seconds. Overall chronic cardiac disease is estimated to cost the EU €210 billion/yr, in direct healthcare costs. All chronic cardiac disease patients are at high risk of stroke, atrial fibrillation, &/or heart failure
The AuriGen platform is single minded in its focus on the leading causes of death in the developed world – Cardiovascular Diseases. Allowing more complex patients to be treated more effectively, and at a lower cost per patient.
AuriGen’s platform of 4 devices is built around our custom cardiac implant, to which we can add synergistic modules such as cardiac monitoring, ablation or both modules. Creating devices which are much more than the sum of their parts, this our key USP. Allowing AuriGen to efficiently & effectively manage the most expensive & sub-optimally treated patients, in a single, safe, fast minimally invasive procedure.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

AURIGEN MEDICAL LIMITED
Net EU contribution
€ 2 499 999,00
Address
18 CHURCHWELL SQUARE
DUBLIN 13 Dublin
Ireland
SME
Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 999 999,75